Literature DB >> 3027709

Association between the expression of the c-myc oncogene mRNA and the expression of the receptor protein for 1,25-dihydroxyvitamin D3.

S C Manolagas, D M Provvedini, E J Murray, S S Murray, P A Tsonis, D A Spandidos.   

Abstract

Studies in lymphocytes have indicated similarities in the state of activation, the time kinetics, and the pathologic states associated with the expression of the c-myc oncogene, and the expression of the 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] receptor protein. Here, we have sought evidence for an association between c-myc and the 1,25-(OH)2D3 receptor protein in mammalian cells other than lymphocytes. Comparing two rat osteogenic sarcoma cell lines, one that produces constitutively relatively high levels of the 1,25-(OH)2D3 receptor protein (ROS 17/2.8) and one in which the 1,25-(OH)2D3 receptor protein is practically undetectable (ROS 2/3), we found that the 1,25-(OH)2D3 receptor-expressing cell line also expressed c-myc mRNA. In contrast, the cell line in which the 1,25-(OH)2D3 receptor was undetectable did not express c-myc mRNA. Furthermore, we transfected mouse skin fibroblasts (NIH 3T3) with a recombinant plasmid carrying the human c-myc oncogene. We found a dramatic increase in the 1,25-(OH)2D3 receptor concentration in five separate clonal lines of NIH 3T3 cells transfected with the c-myc-carrying plasmid compared to their nontransfected counterparts or to NIH 3T3 fibroblasts transfected with the vector plasmid alone. The receptor protein of the transfected cells exhibited biochemical characteristics indistinguishable from those of classical receptors for 1,25-(OH)2D3. The increased expression in the transfected cells appeared specific for the receptor for 1,25-(OH)2D3; receptors for sex steroids were not detected in the nontransfected NIH 3T3 cells and remained undetectable after transfection with c-myc. Moreover, the level of the glucocorticoid receptor protein, which was expressed in the nontransfected cells, did not change upon transfection with c-myc.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027709      PMCID: PMC304315          DOI: 10.1073/pnas.84.3.856

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  Hybridization of nucleic acids immobilized on solid supports.

Authors:  J Meinkoth; G Wahl
Journal:  Anal Biochem       Date:  1984-05-01       Impact factor: 3.365

2.  Glucocorticoids increase the 1,25(OH)2D3 receptor concentration in rat osteogenic sarcoma cells.

Authors:  S C Manolagas; J Abare; L J Deftos
Journal:  Calcif Tissue Int       Date:  1984-03       Impact factor: 4.333

3.  Studies of the internalization of vitamin D3 metabolites by cultured osteogenic sarcoma cells and their application to a non-chromatographic cytoreceptor assay for 1,25-dihydroxyvitamin D3.

Authors:  S C Manolagas; L J Deftos
Journal:  Biochem Biophys Res Commun       Date:  1980-07-31       Impact factor: 3.575

Review 4.  The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins).

Authors:  A W Norman; J Roth; L Orci
Journal:  Endocr Rev       Date:  1982       Impact factor: 19.871

5.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.

Authors:  K Kelly; B H Cochran; C D Stiles; P Leder
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

6.  1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone.

Authors:  C D Tsoukas; D M Provvedini; S C Manolagas
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

7.  1,25-Dihydroxyvitamin D3 receptor-like macromolecule in rat osteogenic sarcoma cell lines.

Authors:  S C Manolagas; M R Haussler; L J Deftos
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

8.  Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite.

Authors:  P H Reitsma; P G Rothberg; S M Astrin; J Trial; Z Bar-Shavit; A Hall; S L Teitelbaum; A J Kahn
Journal:  Nature       Date:  1983 Dec 1-7       Impact factor: 49.962

9.  1,25-dihydroxyvitamin D3 receptors in human leukocytes.

Authors:  D M Provvedini; C D Tsoukas; L J Deftos; S C Manolagas
Journal:  Science       Date:  1983-09-16       Impact factor: 47.728

10.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3.

Authors:  E Abe; C Miyaura; H Sakagami; M Takeda; K Konno; T Yamazaki; S Yoshiki; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

View more
  7 in total

Review 1.  Interactions between surface molecules and the cytoskeleton in the lymphocyte.

Authors:  J C Bennett
Journal:  Trans Am Clin Climatol Assoc       Date:  1988

2.  1,25(OH)2D3 regulates c-myc mRNA levels in tonsillar T lymphocytes.

Authors:  R Karmali; M Hewison; N Rayment; S M Farrow; A Brennan; D R Katz; J L O'Riordan
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

3.  Vitamin D3 inhibits proliferation and increases c-myc expression in fibroblasts from psoriatic patients.

Authors:  M Casado; M Martin; A Muñoz; J Bernal
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

Review 4.  A novel vitamin D-regulated immediate-early gene, IEX-1, alters cellular growth and apoptosis.

Authors:  Rajiv Kumar; Mark R Pittelkow; Jeffrey L Salisbury; Joseph P Grande; Hee-Jeong Im; Kathrin A Feldmann; David Schilling
Journal:  Recent Results Cancer Res       Date:  2003

Review 5.  Vitamin neurotoxicity.

Authors:  S R Snodgrass
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

6.  Expression of calbindin-D28k and its regulation by estrogen in the human endometrium during the menstrual cycle.

Authors:  Hyun Yang; Tae-Hee Kim; Hae-Hyeog Lee; Kyung-Chul Choi; Yeon-Pyo Hong; Peter Ck Leung; Eui-Bae Jeung
Journal:  Reprod Biol Endocrinol       Date:  2011-03-02       Impact factor: 5.211

7.  Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.

Authors:  V Raina; D Cunningham; N Gilchrist; M Soukop
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.